Blood, Journal Year: 2023, Volume and Issue: 143(26), P. 2689 - 2700
Published: July 19, 2023
Language: Английский
Cancer Cell, Journal Year: 2024, Volume and Issue: 42(2), P. 180 - 197
Published: Feb. 1, 2024
The past decade has witnessed significant advances in the systemic treatment of advanced hepatocellular carcinoma (HCC). Nevertheless, newly developed strategies have not achieved universal success and HCC patients frequently exhibit therapeutic resistance to these therapies. Precision represents a paradigm shift cancer recent years. This approach utilizes unique molecular characteristics individual patient personalize modalities, aiming maximize efficacy while minimizing side effects. Although precision shown multiple types, its application remains infancy. In this review, we discuss key aspects HCC, including biomarkers, classifications, heterogeneity tumor microenvironment. We also propose future directions, ranging from revolutionizing current methodologies personalizing therapy through functional assays, which will accelerate next phase advancements area.
Language: Английский
Citations
139
Cell, Journal Year: 2024, Volume and Issue: 187(6), P. 1422 - 1439.e24
Published: March 1, 2024
Language: Английский
Citations
110
Immunity, Journal Year: 2023, Volume and Issue: 56(10), P. 2218 - 2230
Published: Sept. 13, 2023
Language: Английский
Citations
99
Nature, Journal Year: 2023, Volume and Issue: 621(7980), P. 830 - 839
Published: Sept. 6, 2023
Language: Английский
Citations
70
Cancer Cell, Journal Year: 2024, Volume and Issue: 42(2), P. 253 - 265.e12
Published: Jan. 4, 2024
Despite the remarkable success of anti-cancer immunotherapy, its effectiveness remains confined to a subset patients—emphasizing importance predictive biomarkers in clinical decision-making and further mechanistic understanding treatment response. Current biomarkers, however, lack power required accurately stratify patients. Here, we identify interferon-stimulated, Ly6Ehi neutrophils as blood-borne biomarker anti-PD1 response mice at baseline. are induced by tumor-intrinsic activation STING (stimulator interferon genes) signaling pathway possess ability directly sensitize otherwise non-responsive tumors therapy, part through IL12b-dependent cytotoxic T cells. By translating our pre-clinical findings cohort patients with non-small cell lung cancer melanoma (n = 109), public data 1440), demonstrate predict immunotherapy humans high accuracy (average AUC ≈ 0.9). Overall, study identifies functionally active for use both humans.
Language: Английский
Citations
63
Cancer Cell, Journal Year: 2024, Volume and Issue: 42(6), P. 1032 - 1050.e10
Published: May 16, 2024
Total tumor clearance through immunotherapy is associated with a fully coordinated innate and adaptive immune response, but knowledge on the exact contribution of each cell subset limited. We show that therapy-induced intratumoral CD8+ T cells recruited skewed late-stage activated M1-like macrophages, which were critical for effective control in two different murine models cancer immunotherapy. The summon these macrophages into their close vicinity via CCR5 signaling. Exposure non-polarized to supernatant lysate recapitulates tumoricidal phenotype vitro. transcriptomic signature also detected similar macrophage population present human tumors coincides clinical response checkpoint inhibitors. requirement functional co-operation between effector gives warning combinations broad macrophage-targeting strategies.
Language: Английский
Citations
50
Frontiers in Immunology, Journal Year: 2023, Volume and Issue: 14
Published: April 26, 2023
Neutrophils are the most abundant circulating leukocytes in humans and first immune cells recruited at site of inflammation. Classically perceived as short-lived effector with limited plasticity diversity, neutrophils now recognized highly heterogenous cells, which can adapt to various environmental cues. In addition playing a central role host defence, involved pathological contexts such inflammatory diseases cancer. The prevalence these conditions is usually associated detrimental responses poor clinical outcomes. However, beneficial for emerging several contexts, including Here we will review current knowledge neutrophil biology heterogeneity steady state during inflammation, focus on opposing roles different contexts.
Language: Английский
Citations
49
Journal of Hematology & Oncology, Journal Year: 2024, Volume and Issue: 17(1)
Published: April 29, 2024
Abstract Hepatocellular carcinoma (HCC) is a major health concern worldwide, with limited therapeutic options and poor prognosis. In recent years, immunotherapies such as immune checkpoint inhibitors (ICIs) have made great progress in the systemic treatment of HCC. The combination treatments based on ICIs been trend this area. Recently, dual blockade durvalumab plus tremelimumab has also emerged an effective for advanced However, majority HCC patients obtain benefits. Understanding immunological rationale exploring novel ways to improve efficacy immunotherapy drawn much attention. review, we summarize latest area, ongoing clinical trials immune-based therapies, well strategies chimeric antigen receptor T cells, personalized neoantigen vaccines, oncolytic viruses, bispecific antibodies.
Language: Английский
Citations
49
Cell Death and Disease, Journal Year: 2024, Volume and Issue: 15(2)
Published: Feb. 1, 2024
Abstract Although immunotherapy has made breakthrough progress, its efficacy in solid tumours remains unsatisfactory. Exosomes are the main type of extracellular vesicles that can deliver various intracellular molecules to adjacent or distant cells and organs, mediating biological functions. Studies have found exosomes both activate immune system inhibit system. The antigen major histocompatibility complex (MHC) carried make it possible develop them as anticancer vaccines. derived from blood, urine, saliva cerebrospinal fluid be used ideal biomarkers cancer diagnosis prognosis. In recent years, exosome-based therapy great progress fields drug transportation immunotherapy. Here, we review composition sources microenvironment further elaborate on potential mechanisms pathways by which influence for cancers. Moreover, summarize clinical application prospects engineered exosome vaccines Eventually, these findings may open up avenues determining diagnosis, treatment, prognosis
Language: Английский
Citations
45
Molecular Cancer, Journal Year: 2024, Volume and Issue: 23(1)
Published: May 18, 2024
Abstract Neutrophils play a Janus-faced role in the complex landscape of cancer pathogenesis and immunotherapy. As immune defense cells, neutrophils release toxic substances, including reactive oxygen species matrix metalloproteinase 9, within tumor microenvironment. They also modulate expression necrosis factor-related apoptosis-inducing ligand Fas ligand, augmenting their capacity to induce cell apoptosis. Their involvement antitumor regulation synergistically activates network bolstering anticancer effects. Paradoxically, can succumb influence tumors, triggering signaling cascades such as JAK/STAT, which deactivate system network, thereby promoting evasion by malignant cells. Additionally, neutrophil granular constituents, elastase vascular endothelial growth factor, intricately fuel proliferation, metastasis, angiogenesis. Understanding mechanisms that guide collaborate with other cells for comprehensive eradication is crucial enhancing efficacy therapeutics. In this review, we illuminate underlying governing neutrophil-mediated support or inhibition progression, particular focus on elucidating internal external factors polarization. We provide an overview recent advances clinical research regarding therapy. Moreover, future prospects limitations are discussed, aiming fresh insights development innovative treatment strategies targeting neutrophils.
Language: Английский
Citations
45